Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Carbidopa Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.97 |
| ▸ | MAPT | P10636 | 5/20 | 0.97 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.97 |
| ▸ | HPGD | P15428 | 4/20 | 0.97 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.97 |
| ▸ | POLB | P06746 | 3/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.97 |
| ▸ | LMNA | P02545 | 3/20 | 0.97 |
| ▸ | THPO | P40225 | 3/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.97 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.97 |
| ▸ | BLM | P54132 | 4/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | APEX1 | P27695 | 2/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.63 |
| ▸ | USP2 | O75604 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbidopa Anhydrous SCHEMBL1217887 | 1.00 | HSD17B10 (0.97) | HSD17B10KDM4EMAPTTDP1HPGD | |
| Carbidopa Anhydrous SCHEMBL29658622 | 1.00 | HSD17B10 (0.97) | HSD17B10KDM4EMAPTTDP1HPGD | |
| Carbidopa Anhydrous SCHEMBL8407333 | 0.98 | HSD17B10 (1.00) | HSD17B10KDM4EMAPTTDP1HPGD | |
| Carbidopa Anhydrous SCHEMBL30803536 | 0.98 | HSD17B10 (1.00) | HSD17B10KDM4EMAPTTDP1HPGD | |
| Carbidopa Anhydrous SCHEMBL5051647 | 0.98 | HSD17B10 (1.00) | HSD17B10KDM4EMAPTTDP1HPGD | |
| Carbidopa Anhydrous SCHEMBL29392554 | 0.98 | HSD17B10 (1.00) | HSD17B10KDM4EMAPTTDP1HPGD | |
| Carbidopa Anhydrous SCHEMBL35084 | 0.98 | HSD17B10 (1.00) | HSD17B10KDM4EMAPTTDP1HPGD | |
| Carbidopa Anhydrous SCHEMBL2688295 | 0.98 | HSD17B10 (1.00) | HSD17B10KDM4EMAPTTDP1HPGD | |
| Carbidopa Anhydrous SCHEMBL1211698 | 0.97 | KDM4E (0.97) | HSD17B10KDM4EMAPTTDP1HPGD | |
| Carbidopa Anhydrous SCHEMBL19475325 | 0.97 | HSD17B10 (0.97) | HSD17B10KDM4EMAPTTDP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1995027489-A1 | COMPOSITION FOR TREATING NEUROLOGICAL DISORDERS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-10-19 | — | — | WO | claimed |
| EP-0146363-A2 | Synergistic pharmaceutical compositions, their production and use | CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) | 1985-06-26 | — | — | EP | claimed |
| US-20250342933-A1 | Pathology Modifying Neuromodulation Therapy Design | UNIV LELAND STANFORD JUNIOR (US) | 2025-11-06 | — | — | US | disclosed |
| CN-120202511-A | Neuromodulation therapy design to alter pathology | 小利兰·斯坦福大学董事会 | 2025-06-24 | — | — | CN | disclosed |
| WO-2024108082-A1 | ORODISPERSIVE DOSAGE FORMS CONTAINING DROXIDOPA | Aprecia Pharmaceuticals LLC (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024073597-A1 | PATHOLOGY MODIFYING NEUROMODULATION THERAPY DESIGN | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20230050187-A1 | Methods for Treating Parkinson's Disease | MeiraGTx Neuro I, LLC | 2023-02-16 | — | — | US | disclosed |
| EP-4072568-A1 | METHODS FOR TREATING PARKINSON'S DISEASE | Meiragtx UK II Limited (GB) | 2022-10-19 | — | — | EP | disclosed |
| CN-114762684-A | Sustained-release capsule for treating Parkinson and preparation method thereof | 华益泰康药业股份有限公司 | 2022-07-19 | — | — | CN | disclosed |
| WO-2021119615-A1 | METHODS FOR TREATING PARKINSON'S DISEASE | MEIRAGTX UK II LIMITED (GB) | 2021-06-17 | — | — | WO | disclosed |
| WO-2020143843-A1 | ORAL DRUG DELIVERY DEVICE | 上海汉都医药科技有限公司 | 2020-07-16 | — | — | WO | disclosed |
| CN-108349993-A | Brain-penetrating agent chromone oxime derivatives for the treatment of levodopa-induced dyskinesia | 普雷克斯顿医疗股份公司 | 2018-07-31 | — | — | CN | disclosed |
| EP-0497331-B1 | Process for the preparation of tablets or film-coated tablets | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 1996-08-28 | — | — | EP | disclosed |
| WO-1995027489-A1 | COMPOSITION FOR TREATING NEUROLOGICAL DISORDERS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-10-19 | — | — | WO | disclosed |
| EP-0497331-A2 | Process for the preparation of tablets or film-coated tablets | EGIS GYOGYSZERGYAR (HU) | 1992-08-05 | — | — | EP | disclosed |
| US-4880833-A | ANTIDEPRESSANTS, PHENYLALANINE, DEPRENYL, CARBIDOPA | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT (HU) | 1989-11-14 | — | — | US | disclosed |
| US-4880833-A | ANTIDEPRESSANTS, PHENYLALANINE, DEPRENYL, CARBIDOPA | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT (HU) | 1989-11-14 | — | — | US | disclosed |
| EP-0146363-A2 | Synergistic pharmaceutical compositions, their production and use | CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) | 1985-06-26 | — | — | EP | disclosed |
| EP-0146363-A2 | Synergistic pharmaceutical compositions, their production and use | CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) | 1985-06-26 | — | — | EP | disclosed |
| US-4021555-A | Pharmaceutical preparation and method for treatment of parkinsonism | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1977-05-03 | — | — | US | disclosed |